High Isoniazid Resistance Rates in Rifampicin Susceptible Mycobacterium tuberculosis Pulmonary Isolates from Pakistan
Open Access
- 30 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e50551
Abstract
Rapid new diagnostic methods (including Xpert MTB/RIF assay) use rifampicin resistance as a surrogate marker for multidrug resistant tuberculosis. Patients infected with rifampicin susceptible strains are prescribed first line anti-tuberculosis therapy. The roll out of such methods raises a concern that strains with resistance to other first line anti-tuberculosis drugs including isoniazid will be missed and inappropriate treatment given. To evaluate implications of using such methods review of resistance data from high burden settings such as ours is essential. To determine resistance to first line anti-tuberculosis drugs amongst rifampicin susceptible pulmonary Mycobacterium tuberculosis (MTB) isolates from Pakistan. Data of pulmonary Mycobacterium tuberculosis strains isolated in Aga Khan University Hospital (AKUH) laboratory (2009–2011) was retrospectively analyzed. Antimicrobial susceptibility profile of rifampicin susceptible isolates was evaluated for resistance to isoniazid, pyrazinamide, ethambutol, and streptomycin. Pulmonary specimens submitted to AKUH from 2009 to 2011 yielded 7738 strains of Mycobacterium tuberculosis. These included 54% (n 4183) rifampicin susceptible and 46% (n: 3555) rifampicin resistant strains. Analysis of rifampicin susceptible strains showed resistance to at least one of the first line drugs in 27% (n:1133) of isolates. Overall isoniazid resistance was 15.5% (n: 649), with an isoniazid mono-resistance rate of 4% (n: 174). Combined resistance to isoniazid, pyrazinamide, and ethambutol was noted in 1% (n: 40), while resistance to isoniazid, pyrazinamide, ethambutol, and streptomycin was observed in 1.7% (n: 70) of strains. Our data suggests that techniques (including Xpert MTB/RIF assay) relying on rifampicin susceptibility as an indicator for initiating first line therapy will not detect patients infected with MTB strains resistant to other first line drugs (including isoniazid). The roll out of these techniques must therefore be accompanied by strict monitoring ensuring early resistance detection to increase chances of improved patient outcomes.Keywords
This publication has 12 references indexed in Scilit:
- Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan.2012
- Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in QuebecThe International Journal of Tuberculosis and Lung Disease, 2012
- Characterizing Mycobacterium tuberculosis isolates from Karachi, Pakistan: drug resistance and genotypesInternational Journal of Infectious Diseases, 2012
- Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis [Short communication]The International Journal of Tuberculosis and Lung Disease, 2012
- Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patientsScandinavian Journal of Infectious Diseases, 2011
- Treatment Outcomes of Isoniazid-Resistant Tuberculosis Patients, Western Cape Province, South AfricaClinical Infectious Diseases, 2011
- Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysisPLOS Medicine, 2009
- M. tuberculosis Central Asian Strain 1 MDR isolates have more mutations inrpoBandkatGgenes compared with other genotypesScandinavian Journal of Infectious Diseases, 2009
- Isoniazid-Monoresistant Tuberculosis in the United States, 1993 to 2003Archives of internal medicine (1960), 2008
- Genotypic and Phenotypic Characterization of Drug-Resistant Mycobacterium tuberculosis Isolates from Rural Districts of the Western Cape Province of South AfricaJournal of Clinical Microbiology, 2004